Le Lézard
Classified in: Business
Subject: ATY

WeissLaw LLP Investigates Cogentix Medical, Inc. Acquisition


NEW YORK, March 15, 2018 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Cogentix Medical, Inc. ("CGNT" or the "Company") (NASDAQ: CGNT) in connection with the proposed acquisition of the Company by LABORIE Medical Technologies, Inc. ("LABORIE").  Under the terms of the acquisition agreement, the Company's shareholders will receive $3.85 in cash for each CGNT share they own.

WeissLaw is investigating whether CGNT's Board acted to maximize shareholder value prior to entering into the agreement.  Notably, at least one analyst set a target price of $5.00 per share, or $1.15 above the offer price.  Additionally, the Company recently issued a press release preliminarily announcing positive results for the fourth quarter of fiscal year 2017.  It reported that it anticipated preliminary and unaudited revenue of $15.5 million in the fourth quarter of 2017, which would reflect annual increase of approximately 17% when compared to the figures reported in the same period of the prior year. 

Given these facts, WeissLaw is investigating whether CGNT's Board acted in the best interests of CGNT's public shareholders to maximize shareholder value prior to entering into the agreement.  If you own CGNT shares and would like more information about your rights or our investigation, or if you have information to share with us, please contact Joshua Rubin by telephone at (888) 593-4771 or by email at [email protected].

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected] or fill out the form on our website, http://www.weisslawllp.com/cogentix-medical-inc/.

SOURCE WeissLaw LLP


These press releases may also interest you

at 17:37
Alto Adige Wines continues its Digging Deeper Roots campaign in the US market through comprehensive and thoughtful trade and media initiatives. Launched in 2023, the program enhances this Italian region's reach, awareness and understanding with key...

at 17:30
TuanChe Limited ("TuanChe" or the "Company") , a leading integrated automotive marketplace in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the Securities and Exchange Commission...

at 17:30
Chesswood Group Limited ("Chesswood") , a specialty finance company with 40 years of experience in the commercial equipment finance market, today announces an update on its review of strategic alternatives to maximize shareholder value, previously...

at 17:30
The federal government will make a housing announcement in Watson Lake. Media are invited to join Brendan Hanley, Member of...

at 17:28
The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Paychex Inc.  as its "Stock to Study" and Pfizer Inc.  as its "Undervalued Stock" in the June/July 2024 issue for investors' informational and...

at 17:26
NaaS Technology, the first U.S. listed EV charging service company in China, announced remarkable financial growth and operational highlights in its newly-released unaudited financial results for the fourth quarter and full year ended December 31,...



News published on and distributed by: